Skip to main content
OpenTrials
Completed

NCT Number: NCT02197962

Efficacy of Radial Shockwave Therapy for Treatment of Pain in Knee Osteoarthritis

The objective of this study is to compare the results of 2000 impulses of radius shockwaves per week with 2000 placebo shockwaves on the treatment of pain and functional incapacity of patients with severe primary knee osteoarthritis, who did not satisfactory respond to previous conventional treatments.

Completed

Looking for future studies?

Notify Me

Key information

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Instituto de Medicina Fisica e Reabilitacao HCFMUSP, São Paulo, Brazil

Loading trial locations.

About this study

  • Prospective, placebo controlled randomized and double-blind study.
  • Treatment Method:

Radial extracorporeal shockwaves will be applied using the Swiss Dolorclast (EMS Electro Medical Systems, Switzerland), generated by pneumatic waves.

Intervention:

  • Group 1 - Intervention group Patients will receive 2,000 impulses of radial shockwave per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
  • Group 2 - Control Group:

Patients will receive 2,000 impulses of placebo radial shockwave per week, without any energy flow intensity. Frequency of 8Hz will appear in the screen. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.

Post application program for both groups: Three consecutive days of:

  • Hot packs (superficial heat) applied on the application site for 20 minutes;
  • Simple analgesics, when needed (Acetaminophen 500mg every 6 hours, or analogue in case of allergy).

Outcome Evaluation:

The evaluation of pain intensity will be done according to the VAS (Visual Analog Scale) The influence of pain on the functional capacity of patients will be measured with WOMAC (Western Ontario and McMaster Osteoarthritis Index) for knee evaluation.

Another evaluation criteria will be the level of tolerance of pressure on several muscles and other parts as the pes anserinus and patellar tendon, the knee joint interface, and the supraspinal of L1 to S1 also on the dermatomal from T12 to S2. These measures will be done by the Fisher algometry.

The evaluations will be carried out before the treatment, immediately after the treatment and 3 months after the end of the treatment.

Analgesia drut will be prescribed, if patients feel pain during the days after the application.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical and radiological diagnosis of primary knee diagnosis.
  • Pain intensity: Visual Analog Scale (VAS) ≥ 6;
  • One of more failures with conventional treatment (drugs, Non-Steroidal Anti-inflammatory Drugs - NSAD, physiotherapy, stretching, acupuncture, orthosis and others);
  • Age over 60 years;
  • No use of corticosteroids in the prior 48 hours;
  • No major osteoarthritis events in other joints of lower limbs (waist and ankle) and lower back;
  • No clinical evidence of related neuropathy, including radiculopathy and peripheral neuropathy;
  • Absence of systemic inflammatory disease (Rheumatoid arthritis, Reiter, ankylosing spondylitis, generalized polyarthritis, cancer);
  • Absence of infection or cancer at the application site;
  • Absence of related endocrine and metabolic diseases;
  • Absence of fibromyalgia, diagnosed after the American College of Rheumatology, 1999;
  • Absence of severe blood dyscrasias;
  • Absence of severe psychiatric disturbances that requires psychiatric assessment;
  • Availability to comply with the clinic visits and follow up evaluations along the treatment

Exclusion criteria

  • Patients who withdraw the informed consent form at any time

Treatment and study plan

Extracorporeal Radial shockwaves

Device

Patients will receive 2,000 impulses of extracorporeal radial shockwaves or per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.

Placebo Radial Shockwaves

Device

Patients will receive 2,000 impulses of placebo extracorporeal radial shockwaves per week, without any pressure, therefore no energy will be applied, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.

Primary outcomes

  1. Visual Analog Scale

    Time frame: Before intervention and after 3 months of the end of intervention

    The Visual Analog Scale consists of a straight line of 10cm length which presents the phrase "absence of pain" (0) at one extremity, and unbearable pain (10) at the other extremity.

Secondary outcomes

  1. Level of tolerance of pain

    Time frame: Immediately before the intervention, immediately after the intervention and 3 months after the intervention.

    Measures will be taken with the Fisher algometry in the following muscles: vastus medialis, vastus lateralis, rectus femoris, gracilis, adductor longus, tibialis anterior, fibularis longus, quadratus lumborum, iliopsoas and popliteus; also at the pes anserinus and patellar tendon, the knee joint interface, the supraspinal of L1 to S1 and on the dermatomal from T12 to S2.

Other outcomes

  1. The influence of pain over the functional capacity of patients based on the WOMAC questionnaire

    Time frame: Immediately before the intervention and 3 months after the intervention.

Sponsors and collaborators

Lead sponsor

Marta Imamura

Other

Collaborators

  • University of Sao Paulo

Registry information

Important dates

Study start
2010
Primary completion
2015
Study completion
2015
First posted
Jul 23, 2014
Registry last updated
Oct 5, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.